RE:RE:NewsQuattro74 wrote: 58.3 % + 33.3 % = 91.6 % So I think the 4 patients removed from the study potentially hurt our % numbers??? Still better than keytruda and this tech can eventually be applied to those who had to be removed. :-)
Phase one demonstrated that there was a possible dose dependent response. Fixing the dose related issues with the phase 2 patients will also likely increase CR rate. The fact that many of the patients did not receive the approriate dose and still had a 60% CR is suprisingly good.
Fine tuning and get the trial up and running again, short term goals!
Macer